|
Delayed
Japan Exchange
02:30:00 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 22.00 JPY | -4.35% |
|
-4.35% | +10.00% |
Company Valuation: OncoTherapy Science, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 21,689 | 13,292 | 9,054 | 4,353 | 7,606 | 8,057 |
| Change | - | -38.71% | -31.88% | -51.92% | 74.74% | 5.92% |
| Enterprise Value (EV) 1 | 18,790 | 11,456 | 7,937 | 3,826 | 6,773 | 5,968 |
| Change | - | -39.03% | -30.72% | -51.8% | 77.03% | -11.89% |
| P/E | -13.9x | -5.03x | -8.1x | -3.3x | -8.97x | -7.57x |
| PBR | 7.05x | 6.72x | 10.6x | 12.3x | 10.4x | 3.76x |
| PEG | - | -0.1x | 0.1x | -0.77x | 0.2x | 0.7x |
| Capitalization / Revenue | 65.3x | 11.5x | 7.98x | 7.14x | 10.1x | 9.97x |
| EV / Revenue | 56.6x | 9.94x | 7x | 6.27x | 9.03x | 7.39x |
| EV / EBITDA | -11.8x | -5.62x | -7.28x | - | - | - |
| EV / EBIT | -11.5x | -5.58x | -7.17x | -3.42x | -8.5x | -7.37x |
| EV / FCF | -15.7x | -6.43x | -34.2x | -4.08x | -13.2x | -8.84x |
| FCF Yield | -6.36% | -15.6% | -2.92% | -24.5% | -7.57% | -11.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -8.853 | -13.71 | -5.803 | -6.053 | -3.121 | -2.772 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 332 | 1,153 | 1,134 | 610 | 750 | 808 |
| EBITDA 1 | -1,589 | -2,037 | -1,091 | - | - | - |
| EBIT 1 | -1,638 | -2,053 | -1,107 | -1,120 | -797 | -810 |
| Net income 1 | -1,561 | -2,571 | -1,118 | -1,288 | -815 | -910 |
| Net Debt 1 | -2,899 | -1,836 | -1,117 | -527 | -833 | -2,089 |
| Reference price 2 | 123.00 | 69.00 | 47.00 | 20.00 | 28.00 | 21.00 |
| Nbr of stocks (in thousands) | 176,332 | 192,644 | 192,644 | 217,644 | 271,644 | 383,644 |
| Announcement Date | 6/22/21 | 6/21/22 | 6/27/23 | 6/25/24 | 6/24/25 | 6/23/26 |
1JPY in Million2JPY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 60.53M | |
| 20.35x | 7.16x | 14.38x | 1.46% | 69.18B | |
| 31.96x | 9.24x | 44.57x | 0.04% | 62B | |
| -73.2x | 14.15x | -68.23x | -.--% | 26.19B | |
| 29.82x | 6.33x | 16.44x | -.--% | 25.75B | |
| -14.7x | 5.35x | -6.73x | -.--% | 24.29B | |
| 26.87x | 5.1x | 16.96x | -.--% | 19.84B | |
| 45.45x | 16.69x | 33.86x | 0.33% | 15.65B | |
| -14.9x | 3360.83x | -17.18x | -.--% | 13.88B | |
| 1005.79x | 35.18x | 607.6x | -.--% | 14.09B | |
| Average | 117.49x | 384.45x | 71.30x | 0.2% | 27.09B | |
| Weighted average by Cap. | 63.10x | 181.79x | 42.16x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4564 Stock
- Valuation OncoTherapy Science, Inc.
Select your edition
All financial news and data tailored to specific country editions
